MiNK Therapeutics (NASDAQ:INKT - Get Free Report) was downgraded by equities researchers at HC Wainwright from a "buy" rating to a "neutral" rating in a research note issued on Tuesday, July 15th, MarketBeat reports. They currently have a $35.00 target price on the stock. HC Wainwright's target price suggests a potential upside of 111.61% from the company's current price.
Separately, William Blair lowered shares of MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a research report on Friday, July 11th.
Read Our Latest Analysis on INKT
MiNK Therapeutics Stock Performance
NASDAQ:INKT opened at $16.54 on Tuesday. The stock has a market capitalization of $65.99 million, a P/E ratio of -6.56 and a beta of 0.19. The company has a 50 day moving average price of $12.24 and a 200 day moving average price of $9.75. MiNK Therapeutics has a fifty-two week low of $4.56 and a fifty-two week high of $76.00.
MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last announced its quarterly earnings results on Thursday, May 15th. The company reported ($0.70) EPS for the quarter, missing the consensus estimate of ($0.61) by ($0.09). Research analysts forecast that MiNK Therapeutics will post -2.75 earnings per share for the current fiscal year.
About MiNK Therapeutics
(
Get Free Report)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Further Reading
Before you consider MiNK Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.
While MiNK Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
